Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

vaccine banenr

Editorial

Perceptions of Human Tuberculosis Vaccine: The Fiocruz Latest Contribution

Paulo RZ Antas*

Laboratory of Clinical Immunology, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil

Submitted: 05-26-2014 Accepted:  05-27-2014 Published: 06-02-2014

Download PDF

_________________________________________________________________________________________________________________________

 

Article

 
As globally reported, tuberculosis (TB) is a major cause of illness and death worldwide, with increased burden mainly in developing countries. The Stop TB Partnership goals embrace dropping the global TB burden by half in 2015 and eliminating TB as a public health problem by 2050. As an ancient microbe highly adapted to the host, Mycobacterium tuberculosis infects humans through an oral route. TB can be caught by persons that inhale droplets containing the bacteria when an infected person coughs or sneezes. But the majority of these infected subjects will remain asymptomatic. In fact, this huge reservoir is blamed for the TB burden mainly in developing countries, causing the global resurgence of TB, which is further fueled by the HIV pandemic and the rise of M. tuberculosis multi (MDR)-,extremely (XDR)-, and totally (TDR)-drug resistant strains.

Importantly, vaccination is a key approach in reducing the frequency of TB. M. bovis bacillus Calmette–Guérin (BCG), the only licensed TB vaccine currently in use, was first administered orally in 1921, and since then many clinical trials in different parts of the world have evaluated the effectiveness of BCG in preventing TB disease. These trials demonstrate that BCG confers steady protection against extrapulmonary TB in children. However, BCG affords extremely inconsistent defense against pulmonary TB, which accounts for the major burden of global TB mortality and morbidity throughout the world. Therefore, a more successful vaccine is a major global health priority by governments. The Moreau BCG strain has been employed for some 70 years here in Brazil and lessons from its use should be taken in account for the development or improvement of new TB vaccines. In this venue, the challenges for the subsequent forthcoming years are obvious. It is improbable that any simple immunological correlate of protection will be recognized. Therefore, it is essential our understanding on how BCG confers protection. The vast majority of the current population has been vaccinated with BCG, with the possible requirement for a booster immunization in adulthood for TB protection. BCG Moreau strain also protects against leprosy, meningitis and extrapulmonary forms  of TB. Factors related to differences in strain, dosage andBCG administering protocol have been responsible for the variable efficacy. This vaccine is clearly affected by, as yet unclear, host and/or environmental variables. Yet, little is known about the interaction of BCG with human monocytes. Also in preclinical studies, IFNγ seems to be required but not sufficient for protection, and the magnitude of the immune response correlates with the degree of protection. However, any immunological correlate may be vaccine and disease-stage specific.

One of our central goals is to investigate the potential of BCG Moreau strain to induce in vitro specific cell-death in BCG-stimulated monocytes from healthy adults. There was a concomitant release of IL-1β and TNF-α, but not metalloproteinase (MMP)-9. In addition, there was an enhancement of monocytes necrosis, but not apoptosis, following BCG Moreau strain stimulation of umbilical vein cells from naïve, neonate population. This pattern was paralleled by different pro-inflammatory cytokine levels, as well as MMP-9 induction when compared to the adults. Those findings support the hypothesis that BCG induces distinct cell-death patterns during the maturation of the immune system and that this pattern might set the stage for a subsequent antimycobacterial immune response that might have profound effects during vaccination. In another small study, the in vitro Th1-immune response of neonates (IFNγ) was shown to be deficient when cells were placed in contact with recombinant antigens by an ELISPOT assay. In fact, the probable impairment was related to a non-specific immune response, since a potent mitogen assayed in parallel as an internal positive control yielded virtually no response in that group. Also, cells from vaccinated adult individuals in matching identical assays, yielded convincing data. The reasons behind this result are speculative; perhaps due to a higher amount of circulating immature immune cells or to a lack of exposure to mycobacterial antigens.

M. tuberculosis is an extremely well-adapted pathogen which has co-existed with the human host for millennia, and it has learned how to modulate potentially protective host responses to ensure its own survival. Therefore, tuberculosis currently presents distinctive challenges to vaccine development not faced in other diseases. In addition, the candidates for novel vaccines against TB based on diverse BCG platforms are valuable tools for TB control. The most promising ones in current clinical trials were derived from BCG strains. It hindsight, greater representation of BCG strains from the most immunogenic group may have led to candidates with higher efficacy than existing strains.

Finally, advances in the fields of immunology and molecular biology have stimulated research into new vaccination techniques for TB and alternative approaches are warranted in the next few years in order to develop more reliable tools to induce a protective immune response against this disease. In sum, series of quality articles inform and still convey our observational assessments in order to compile a message for those interested in the TB vaccinology. Therefore, our reputation in the field, the Fiocruz institutional history, and the relevance of tackle TB are our major focus. Particularly, the BCG vaccine, Moreau strain, is our main point of interest, and also the current relevance in public health at Fiocruz.
 

References

References

1.Chriss PM, Sheposh J, Carlson B, Riegel B. Predictors of successful heart failure self-care maintenance in the first three months after hospitalization. Heart Lung. 2004, 33(6): 345-353.

2.Carlson B, Riegel B, Moser D. Self-care abilities of patients with heart failure. Heart and Lung. 2001, 30(5): 351-359.

3.Riegel B, Dickson VV. A situation-specific theory of heart failure self-care. J Cardiovasc Nurs. 2008, 23(3): 190–196.

4.Van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH et al. Compliance in heart failure patients: the importance of knowledge and beliefs. European Heart Journal. 2006, 27(4): 434-440.

5.Caldwell MA, Peters KJ, Dracup KA. A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural settings. American Heart Journal. 2005, 150(5): 983.

6.Albert, N. Promoting self-care in heart failure: State of clinical practice based on the perspectives of healthcare systems and providers. Journal of Cardiovascular Nursing. 2008, 23(3): 277-284.

7.Jaarsma T, Halfens R, Tan F, Abu-Saad HH, Dracup K et al. Self-care and quality of life in patients with advanced heart failure: the effect of a supportive educational intervention. Heart and Lung. 2000, 29(5): 319-330.

8.Uchmanowicz I, Łoboz-Rudnicka M, Szeląg P, Jankowska-Polańska B, Łoboz-Grudzień K. Frailty in heart failure Curr.Heart.Fail.Rep. 2014, 11(3): 266-273.

9.Lupón J, González B, Santaeugenia S, Altimir S, Urrutia A et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Rev Esp Cardiol. 2008, 61(8): 835–842.

10.McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL et al. Measuring frailty in heart failure: a communityperspective. 2013, 166(4): 768–774.

11.Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM et al. Frailty consensus: a call to action. 2013, 14(6): 392–397.

12.Afilalo J, Alexander KP, MackMJ, Maurer MS, Green P et al. Frailty assessment in the cardiovascular care of older adults. 2014, 63(8): 747–762.

13.Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C et al. Frailty in older adults: evidence for a phenotype. 2001, 56(3): 146–156.

14.Cacciatore F, Abete P, Mazzella F, Viati L, Della Morte D, D et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. 2005, 35(12): 723–730.

15.Lupon J, Gonzalez B, Santaeugenia S, Altimir S, Urrutia A et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. 2008, 61(8): 835–842.

16.Chaudhry SI, Wang Y, Gill TM, Krumholz HM. Geriatric conditions and subsequent mortality in older patients with heart failure. 2010, 55(4): 309–316.

17.Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM. Toward a conceptual definition of frail community dwelling older people. 2010, 58(2): 76–86.

18.Artinian NT, Magnan M, Sloan M, Lange MP. Self-care behaviors among patients with heart failure. Heart Lung. 2002, 31(3), 161-172.

19.Bushnell, FK. Self-care teaching for congestive heart failure patients. 1992, 18(10): 27-32.

Cite this article: Paulo R Z A. Perceptions of Human Tuberculosis Vaccine: The Fiocruz Latest Contribution. J J Vaccine Vaccination. 2014, 1(1): 001.

Contact Us:
9600 GREAT HILLS
TRAIL # 150 W
AUSTIN, TEXAS
78759 ( TRAVIS COUNTY)
E-mail : info@jacobspublishers.com
Phone : 512-400-0398